PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents
PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents
批准号:
7747829
负责人:
Joel R Morgan
金额:
$35.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-21 至 2011-08-31
关键词:
AnatomyAnimal ModelAntisense OligonucleotidesAutomationBiological SciencesBypassCaenorhabditis elegansCell Culture TechniquesCell modelCellsChemicalsChemistryCleaved cellComputer softwareDNADataDatabasesDevelopmentDrosophila genusEmbryoEquipmentGene ExpressionGenerationsGenesGoalsHydrogen BondingLightLocationLuciferasesMarketingMessenger RNANorth CarolinaNucleosidesNucleotidesOpticsOrganOrganismPathway interactionsPhasePhenotypeReagentReporterResearch PersonnelResolutionRoleRouteSiteSmall Business Innovation Research GrantStagingSystemTechnologyTestingTexasTimeUltraviolet RaysUniversitiesWhole OrganismWorkZebrafishbasechemical geneticschordindigitalinstrumentinstrumentationirradiationknock-downmonomernovelpreventpublic health relevanceresearch studyspatiotemporalsuccesstoolultraviolet irradiation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The spatiotemporal modulation of gene expression using targeted light to activate antisense molecules promises to have an important impact in transparent model organisms, where irradiation can be specifically targeted visually to known anatomic landmarks. Irradiating selected cells within organs permits specific genes to be turned off at any time during the development of the organism with cell-scale resolution, thereby permitting an in depth spatiotemporal understanding of the role of particular genes in the whole organism. This also allows the study of genes essential in early development that otherwise result in a lethal phenotype. We have developed a commercial reagent, software and instrumentation platform for conducting spatiotemporal gene-control experiments. Leveraging off these initial successes, we now aim to further develop and commercialize a new generation of photoactivatable antisense reagents (PhotoMorph3.0" and PhotoPS3.0"). The proposed photoactivatable antisense reagents are based on morpholino or phosphorthioate oligomers that are protected on their exocyclic hydrogen bond donors and acceptors with photolabile caging groups that disrupt Watson-Crick pairing with a target mRNA. Light irradiation cleaves the caging groups, freeing the bases to participate in hybridization with the target. We hypothesize that exocyclic base protection will offer important advantages over other photoactivatable formats, including a 'tight' off-state and facile on-demand access using automation. The goal of this Phase I SBIR is to make the photoactivatable antisense chemistry robust for commercial-scale synthesis and implementation. The goal of the Phase II SBIR will be to develop validated and turn-key "tool-kits" for various developmental pathways (e.g. gut400, CNS500), where the basic phenotype of each photoactivatable antisense reagent will be described and made available in a public database for researchers.
PUBLIC HEALTH RELEVANCE: The modulation of gene expression at different times and locations using targeted light to activate molecules promises to have an important impact in transparent model organisms, where irradiation can be specifically targeted visually to known anatomic landmarks. Irradiating selected cells within organs permits specific genes to be turned off at any time during the development of the organism with cell-scale resolution, thereby permitting an in depth understanding of the role of particular genes in different locations in the whole organism and at different times during its development. We now aim to further develop and commercialize a new generation of photoactivatable chemicals for doing this (PhotoMorph3.0" and PhotoPS3.0") that we believe will offer important advantages over others.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB
-
批准号:8317529
-
项目类别:
-
资助金额:$28.07万
-
财政年份:2011
-
负责人:Joel R Morgan
-
依托单位:
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB
-
批准号:8121904
-
项目类别:
-
资助金额:$27.1万
-
财政年份:2011
-
负责人:Joel R Morgan
-
依托单位:
99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
-
批准号:7906159
-
项目类别:
-
资助金额:$29.51万
-
财政年份:2010
-
负责人:Joel R Morgan
-
依托单位:
99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
-
批准号:8133718
-
项目类别:
-
资助金额:$29.51万
-
财政年份:2010
-
负责人:Joel R Morgan
-
依托单位:
Snap-To-It Probes
-
批准号:7940065
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:Joel R Morgan
-
依托单位:
Snap-To-It Probes
-
批准号:7920747
-
项目类别:
-
资助金额:$13.73万
-
财政年份:2002
-
负责人:Joel R Morgan
-
依托单位:
Snap-To-It Probes
-
批准号:7501444
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2002
-
负责人:Joel R Morgan
-
依托单位:
Snap-To-It Probes
-
批准号:7405287
-
项目类别:
-
资助金额:$23.7万
-
财政年份:2002
-
负责人:Joel R Morgan
-
依托单位:
Snap-To-It Probes
-
批准号:7674799
-
项目类别:
-
资助金额:$51.11万
-
财政年份:2002
-
负责人:Joel R Morgan
-
依托单位:
海外基金